Return to University Health's Homepage.

Kermit Speeg, MD

UT Health San Antonio
Board Affiliation/Certification
American Board of Internal Medicine
University of Texas Southwestern Medical School, 1972
Vanderbilt University Hospital & Clinic, 1974
University of Texas Health Science Center, 1977
Vanderbilt University Hospital & Clinic, 1977


  1. Nguyen NTT, Ha CP, Harring TR, Chu D, Kar B, O‘Mahony C, Bakaeen F, Washburn WK, Halff GA, Goss JA, Speeg KV.Dilated Cardiomyopathy after Orthotopic Liver Transplantation: A Multi-Institution Report of Six Cases Treated with Mechanical Assist Devices 2011 Jan. (Hepatology; vol. 54, no. 661).
  2. Lytvak I, Prihoda TJ,Speeg KV, Washburn WK, Halff GA, Sharkey FE.Microsteatosis More Significant Than Macrosteatosis in Predicting Early Post Transplant Hepatic Non-Function 2010 Mar. (Modern Pathology; vol. 23, no. 364A).
  3. Cura M, El-Merhi F, SURI R, Lopera JE, Speeg KV, Guerrero JA, Washburn WK, Halff GA.Transplant free survival (TFS) after Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation with the Viatorr covered-stent. 2010. (Cardiovascular and Interventional Radiological Society of Europe).
  4. Cura M, Speeg KV, El-Merhi F, SURI R, Lopera JE, Washburn WK, Halff GA.Transjugular intrahepatic portosystemic shunts (TIPS) creation in recurrent hepatitis C (HCV) cirrhosis after Liver Transplantation (LT). 2010. (Cardiovascular and Interventional Radiology Society of Europe).
  5. Dwivedi S, Berg MW, Eidem M, Speeg KV, Guerrero JA, Nazario H, Patel S.Endoscopic Ultrasound-Guided Pericardiocentesis in a Patient With Disseminated Cryptococcus Infection 2009 Apr. p. S240. (Gastrointestinal Endoscopy; vol. 69, no. 2).
  6. Hall RC, Speeg KV, Riley DJ, Gister C, Maxwell PR.Evaluation of risk factors for central pontine myelinolysis after liver transplantation. 2009. (Poster at American Transplant Congress).
  7. Hall RC, Maxwell PR, Speeg KV, Green BK, Lewis J.Predictors of Outcomes in Hepatitis C-Related Liver Transplants: How are we doing? Dallas, Texas: 2008 Apr. (proceedings from Alcalde Regional Residency Leadership Conference).
  8. Guerrero JA, Speeg KV.HCV Ab Negative HCV Infection in a Kidney Transplant 2005 Oct. (American Journal of Gastroenterology).
  9. Washburn WK, Nichols, L, Mejia A, Speeg KV, Halff GA.Recipient MELD Score and Resource Utilization: Higher is Higher. Presented at the American Transplant Congress, Seattle, WA: 2005 May. p. 425. (American Journal of Transplantation; vol. 5, no. s11).
  10. Guerrero J, Speeg KV.HCV-Ab negative HCV infection in a kidney transplant recipient. Poster at the American College of Gastroenterology. 2005: 2005 May.
  11. Pollack MS, Speeg KV, Callander NS, Freytes CO, Halff GA.Severe graft versus host disease manifesting eight months after liver transplantation 2004. p. S63-S63. (Human Immunology; vol. 65).
  12. Washburn WK, Speeg KV, Guerrero JA, Havranek R, Esterl RM, Abrahamian GA, Cigarroa FG, Halff GA.MELD: Impact of Hepatocellular Carcinoma on the Adult Liver Transplant Waiting List 2003. p. 374A. (Hepatology; vol. 38).
  13. Pollack MS, Speeg KV, Nolan III CR, Washburn WK, Esterl RM, Abrahamian GA, Halff GA.Successful Combined Liver/Kidney Transplantation in Highly Sensitized, Crossmatch Positive Patients. 2002 Oct. p. S74. (Human Immunology; vol. 63, no. 10).
  14. Pollack MS, Havranek, R, Halff GA, Esterl RM, Washburn WK, Cigarroa FG, Speeg KV.Liver Transplant Recipients with Positive T-cell Cross-matches Have Excess Mortality. 2000 Oct. p. s91-s91. (Human Immunology; vol. 61, no. Sup 2).
  15. Washburn WK, Speeg KV, Esterl RM, Tourtellot C, Pollack MS, Halff GA.Liver Transplantation Using Minimal Steroids, Prograf, Cellcept, and Daclizumab. 2000. p.S166-S166. (Transplantation; vol. 69, no. 8).
  16. Speeg KV, Gross GW.Effects of cholestasis on cimetidine sulfoxidation. 1990 Apr.p. A635. (Gastroenterology; vol. 98).

Book Chapters

  1. Espinoza A, Speeg KV, Washburn K, Halff G.Liver Transplantation In: Espinoza A, Speeg, Washburn K, Halff G. Essential Emergency Medicine for the Healthcare Practitioner. Saunders-Elsevier; 2007.
  2. Speeg KV, Halff GA, Schenker S.Metabolism of drugs before and after liver transplantation. In: Maddrey WC, Schiff E, Sorrell MF. Transplantation of the Liver, 3rd Ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
  3. Speeg KV, Bay MK.Prevention and Treatment of Drug-Induced Liver Disease In: Lewis J.H.. Gastroenterology Clinics of North America. Philadelphia: W.B. Saunders; 1995.


  1. Schenker S, Speeg KV.The Risk of Alcohol Intake in Men and Women: All May Not Be Equal! N Engl J Med 1990;322:127-129.
  2. Schenker S, Desmond PV, Speeg KV, Hoyumpa AM.Cryptic nature of bromacriptine therapy in portal systemic encephalopathy. Gastroenterology 1980 May;78(5Pt1):1094-1097.

Journal Articles

  1. Lee SM, Speeg KV, Pollack MS, Sharkey FA.Progression of morphologic changes after transplantation of a liver with heterozyzous alpha-1 antitrypsin deficiency Human Pathology 2012;43:753-756.
  2. Sharkey FE, Lytvak I, Prihoda TJ, Speeg KV, Washburn WK, Halff GA.High-grade Microsteatosis and Delay in Hepatic Function after Orthotopic Liver Transplantation Human Pathology 2011:1337-1342.
  3. Cura MA. Postoak D. Speeg KV. Vasan R..Transjugular Intrahepatic Portosystemic Shunt for Variceal Hemorrhage due to Recurrence of Hereditary Hemorrhagic Telangiectasia in a Liver Transplant Journal of Vascular and Interventional Radiology 2010;21:135-139.
  4. Wang Y, Speeg KV, Washburn WK, Halff G.Sirolimus plus Sorafenib in Treating a Patient with HCC Recuurence Post-Liver Transplantaion. World Journal of Gastroenterology 2010:5518-5522.
  5. Washburn WK, Pollock BH, Nichols L, Speeg KV, Halff G.Impact of recipient MELD score on resource utilization. Am J Transplant 2006 Oct;6(10):2449-2454.
  6. Pollack MS, Speeg KV, Callander NS, Freytes CO, Espinoza AA, Esterl RM, Abrahamian GA, Washburn WK, Halff GA.Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol 2005 Jan;66(1):28-31.
  7. Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA.Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004 Apr;231 (1):231-236.
  8. Lovell MO, Speeg KV, Havranek RD, Sharkey FE.Histologic changes resembling acute rejection in a liver transplant patient treated with terbinafine. Hum Pathol 2003 Feb;34(2):187-189.
  9. Baughman SM, Speeg KV.Use of orthopedic traction device for Sengstaken- Blakemore counter-traction. Contemp Surg 2003;59:378.
  10. ettally CA, Speeg KV.Infection with Listeria monocytogenes following orthotopic liver transplantation: Case report and review of the literature. Liver Tranplant Proc 2003;35:1485-1487.
  11. Ferral H, Vasan R, Speeg KV, Serna S, Young C, Postoak DW, Wholey MH, McMahan CA.Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol 2002 Nov;13(11):1103-1108.
  12. Postoak DW, Ferral H, Washburn WK, Speeg KV, Wholey MH.Transjugular intrahepatic portosystemic shunt creation in a patient with situs inversus. J Vasc Interv Radiol 2002 Jul;13(7):755-756.
  13. Mejia A, Halff GA, Esterl R, Cigarroa F, Speeg KV, Villarreal R, Washburn K.Outcome of Liver Transplantation in Hispanics versus Non-Hispanics: Is There a Difference? Transplant Proc 2002 Jun;34(4):1236-1238.
  14. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G.Steroid Elimination 24 hours After Liver Transplantation Using Daclizumab, Tacrolimus, and Mycophenolate Mofetil. Transplantation 2001 Nov;72(10):1675- 1679.
  15. Schenker S, Speeg KV, Perez A, Finch J.The effects of food restriction in man on hepatic metabolism of acetaminophen. Clin Nutr 2001 Apr;20(2):145-150.
  16. Patterson JE, Peters J, Calhoon JH, Levine S, Anzueto A, Al-Abdely H, Sanchez R, Patterson TF, Rech M, Jorgensen JH, Rinaldi MG, Sako E, Johnson S, Speeg V, Halff GA, Trinkle JK.Investigation and Control of Aspergillosis and Other Filamentous Fungal Infections in Solid Organ Transplant Recipients Transpl Infect Dis 2000 Mar;2(1):22-28.
  17. St Laurent M, Esterl RM, Halff GA, Speeg KV.Gallbladder Carcinoma Producing Alpha-fetoprotein. J Clin Gastroenterol 1999 Mar;28(2):155-158.
  18. Barnes CJ, Hamby-Mason RL, Hardman WE, Cameron IL, Speeg KV, Lee M.Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomark Prevent 1999;8:311-315.
  19. Cai TH, Esterl RM, Nichols L, Cigarroa F, Speeg KV, Halff GA.Improved Immunosuppression with Combination Tacrolimus (FK506) and Mycophenolic Acid in Orthotopic Liver Transplantation. Transplant Proc 1998 Jun;30(4):1413-1416.
  20. Lahiri SA, Halff GA, Speeg KV, Esterl RM.Indium-111 WBC Scan Localizes Infected Hepatic Cysts and Confirms Their Complete Resection in Adult Polycystic Disease. Clin Nucl Med 1998;23(1):33-34.
  21. Esterl RM, St Laurent M, Bay MK, Speeg KV, Halff GA.Stent Migration and Small Bowel Perforation After Endoscopic Biliary Stent Placement in a Liver Transplant Recipient. J Clin Gastroenterol 1997 Mar;24(2):106-110.
  22. Hardman WE, Cameron IL, Beer WH, Speeg KV, Kadakia SC, Lang KA.Transforming growth factor a Distribution in rectal crypts as a biomarker of decreased colon cancer risk in patients consuming cellulose. Cancer Epidemiology, Biomarkers and Prevention 1997;6:633-637.
  23. Halff GA, Esterl RM, Speeg KV.The Use of Cellcept to Minimize Prograf Toxicity in Early Post-operative Liver Transplant Patients with Renal Insufficiency. J Hepatology 1996;25:203-203.
  24. Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV.Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology 1991;14:1013-1015.
  25. Leighton J, Bay MK, Maldonado AL, Johnson RF, Schenker S, Speeg KV.The effect of liver dysfunction on colchicine pharmacokinetics in the rat. Hepatology 1990;11:210-215.
  26. Meredith CG, Muhoberac BB, Gray JP, Speeg KV, Dunn D, Hoyumpa AM, Schenker S.Hepatic oxidative drug metabolism and the microsomal mileau in a rat model of congenital hyperbilirubinemia. Biochem Pharmacol 1986 Nov;35(21):3831-3837.
  27. Nelson DC, Avant GR, Speeg KV, Hoyumpa AM, Schenker S.The effect of cimetidine on hepatic drug elimination in cirrhosis. Hepatology 1985 Mar;5(2):305-309.
  28. Mitchell M, Schenker S, Speeg KV Jr.Selective Inhibition of Acetaminophen Oxidation and Toxicity by Cimetidine and Other Histamine H2-Receptor Antagonists in vivo and in vitro in the Rat and in Man. J Clin Invest 1984;73:383-391.
  29. Speeg KV Jr, Patwardhan R, Avant R, Mitchell M, Schenker S.Inhibition of Microsomal Drug Metabolism by Histamine H2-Receptor Antagonists Studied in vivo and in vitro in Rodents. Gastroenterology 1981;81:1052-1060.
  30. Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg KV Jr.Lack of Tolerance and Rapid Recovery of Cimetidine Inhibited Chlordiazepoxide (Librium) Elimination. Gastroenterology 1981;81:547-552.
  31. Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KV Jr.Cimetidine Spares the Glucuronidation of Lorazepam and Oxazepam. Gastroenterology 1980;79:912-916.
  32. Lopera JE, Speeg KV, Garg D, Michalek J, Kroma G, Suri R, Castaneda-Zuniga W.Effect of Liver Volume in Morbidity and Mortality after elective TIPS.
  33. Poordad F, Lawitz E, Gutierrez J, Guerrero J, Speeg KV, Swenson ES.An HCV Positive Recipient of an HCV-Postive Donor Liver Successfully treated Before and Immediately After Liver Transplantation with Daclatasvir, Sofosbuvir and Ribavirin American J Transplantation.
Patient reviews
    Download our mobile app
    Access health information, find a doctor, get directions or view maps, and more.